|
You are subscribed to Oncology (Cancer) / Hematologic Malignancies. This information has recently been updated, and is now available.
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.
|
This email was sent to Minuty@podam.pl using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·
10903 New Hampshire Ave · Silver Spring, MD · 20993-0002 · 1-888-INFO-FDA |
 |
|
|
